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ABSTRACT 
Fy blood group antigens are carried by Duffy Antigen Receptor for Chemokines (DARC), a red cells 
receptor for Plasmodium vivax broadly implicated in human health and diseases. Recombinant VHHs, 
or nanobodies, the smallest intact antigen binding fragment derivative from the heavy chain-only 
antibodies present in camelids, were prepared from a dromedary immunized against DARC N-
terminal extracellular domain and selected for DARC binding. Described VHH, CA52 does recognize 
native DARC on cells . It inhibits P. vivax invasion of erythrocytes and displaces interleukin-8 bound 
to DARC. The targeted epitope overlaps the well defined DARC Fy6 epitope. KD of CA52-DARC 
equilibrium is sub-nanomolar hence ideal to develop diagnostic or therapeutic compounds. 
Immunocapture by immobilized CA52 yielded highly purified DARC from engineered K562 cells. 
This first report on a VHH with specificity for a red blood cell protein exemplifies VHHs' 
potentialities to target, to purify and to modulate the function of cellular markers. 
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INTRODUCTION  
 
DARC or Duffy Antigen Receptor for Chemokines is a protein of the human red cell membrane of 
paramount importance for human health [1-3]. It is a blood group protein: two antithetic antigens have 
been described, Fya and Fyb, corresponding to a single polymorphism in the extracellular part of the 
molecule [4]. Another antigen named Fy3 is less precisely defined at the molecular level, and may be 
responsible for human alloimmunization. A fourth important antigen present on both Fya and Fyb 
allotypes is called Fy6, it was defined through monoclonal antibodies preparation [5-6] though no 
human antiserum exists which recognizes it. Two other genetic conditions have to be mentioned: one 
relatively rare called Fyb-weak corresponds to the low level membrane expression of the protein at the 
red cell surface, the point mutation in reading frame linked to this condition has been elucidated [7]. 
The other, called Fy-negative, is very widespread among the West African blacks (98%) and African 
Americans (68 %) and characterized by the specific extinction of DARC expression on cells of the 
erythrocytic lineage [1]. People with this genetic property are said to be Duffy- or Fy-negative. This 
selective extinction is due to a mutation in a GATA box of DARC promoter region [8]: the GATA 
transcription factor is driving DARC expression in cells from the erythrocytic lineage while other 
factors are operative in tissues where DARC is expressed like endothelial cells from the post capillary 
venules, Purkinje cells, epithelial cells in the kidney collecting duct [9-10]. The Fy-negative phenotype 
has been found in Caucasian people but it is linked to deletion or point mutations in the reading frame 
of DARC [11].  
The linkage of DARC to human pathology was discovered some forty years ago when it was shown 
that Fy-negative people were resistant to malaria induced by Plasmodium vivax [12]. The role of 
DARC as a receptor for P. vivax merozoite was confirmed by several reports including detailed 
molecular studies on DARC and P. vivax Duffy Binding protein (PvDBP) [13-16]. Furthermore, these 
studies created hope that vaccination against P.vivax malaria might be possible [17-18], however this 
notion is challenged by recent observations which suggest that resistance of Fy-negative red cells to 
invasion is not as absolute as originally anticipated [19-21].  
Cloning of DARC cDNA [22] and of its gene [23], and the discovery in the early nineties that DARC 
is a ligand for chemokines [24] were milestones in DARC studies. Indeed, DARC binds numerous 
chemokines of both the CC and CXC group [25]. DARC has the topology characteristic of the 7TM 
domain GPCR family; however, the intracellular DRY sequence which is necessary for GPCR to 
interact with G protein and trigger an activation cascade in response to an extracellular stimulus is 
missing in DARC. Three other 7TM GPCR-like proteins namely D6, CCXCKR and CXCR7 are 
known, they also bind several chemokines and are called collectively chemokines interceptors or 
atypical chemokines receptors [26]; even though several uncertainties remain regarding their exact 
physiological role, they are thought to participate in the regulation of the chemokines network. With 
regard to DARC, today a galore of epidemiological and experimental data, on whole organisms (e.g. 
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genetically modified mice) and on isolated cells as well, do suggest that DARC is involved in cancer 
development and its metastatic potential [27-30], in inflammation and in inflammatory disease [31-
38]. Mechanisms which might explain the role of DARC are far from clear in many cases but there is a 
growing consensus that chemokine binding is probably central to the pleiotropic effects of DARC [36-
38]. Lastly it should be mentioned that DARC might be involved in HIV binding to red cells, HIV 
contamination and AIDS progression but the ongoing studies led to somewhat conflicting results [39-
45].  
 
Taking into account the certain but complex role of DARC in human diseases we decided to develop 
new tools for DARC studies based on VHHs, i.e. the recombinant derivatives of camelid 
immunoglobulins. Two IgG subclasses of camelid immunoglobulins are composed of heavy chains- 
only and lack all light chains [46]. The variable region of these heavy chains-only antibodies is easily 
cloned from lymphocytes from naive or immunized camelids. These fragments, known as VHHs or 
nanobodies are the smallest intact antigen-binding fragment derivative endowed with the properties of 
an authentic antibody. The VHHs are famed for a good expression yield and an excellent solubility 
compared to most mice or human two chains derived antibody fragments [review in 47]. They may be 
used in a range of assays [48], for protein purification [49], and as an aid to crystallization [50]. 
Multiple therapeutic and diagnostic agents have been or are being developed from VHHs [51-52] 
We immunized a dromedary with the N-terminal extracellular domain of DARC expressed in E. coli. 
This domain (referred to as ECD1) carries the polymorphic site responsible for the Fya/Fyb allotypes, 
the Fy6 epitope and participates in the binding of chemokines and PvDBP. We built a VHH library 
from dromedary's lymphocytes and screened this bank for antigen-specific VHHs using also E. coli 
produced proteins. Several DARC-specific VHHs were obtained, and in this report we further focus on 
one of these, referred to as CA52. The linear epitope of CA52 was identified, CA52 is perfectly able to 
recognize the glycosylated protein present on human cells, although the immunogen was a non 
glycosylated protein. Furthermore, CA52 interferes with the interleukin-8 binding to DARC and 
P.vivax infection of red blood cells. Moreover, the CA52 attachment to a gel generates a powerful 
adsorbent to purify native DARC in a single step from a detergent extract of cells. 
 
 
MATERIALS AND METHODS 
 
Prokaryotic constructs for immunisation of the dromedary, library screening and preliminary 
epitope mapping of the VHH 
The antigens used for immunization were derived from DARC ECD1. The two allotypic variants of 
ECD1 with wild type sequences and also ECD1 in which tyrosine 30 and 41 had been mutated to Glu 
(in order to mimic sulphated tyrosines [15]) were fused at the N-terminus of Staphylococcus aureus 
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nuclease. Proteins used for screening contained wild type ECD1 sequences fused to the C-terminus of 
GST (pGEX vector, GE Healthcare). Other ECD1-nuclease constructs were prepared in which 
deletions were introduced in ECD1 to facilitate quick identification of epitope location recognized by 
VHH. Sequences of all constructs are shown in Table 1. 
ECD1 variants fused to Staphylococus aureus nuclease were cloned to a plasmid obtained as a much 
appreciated gift from Prof. D. Engelman from Yale University. It is an early variant of the T7 family 
of plasmids [53].  
All proteins were produced in BL21 E. coli cells (Stratagene La Jolla CA) grown in autoinduction 
medium [54]. Whole cell extracts were obtained by passing bacterial pellet through an Emulsiflex-C5 
Avestin (Ottawa, Canada) homogenizer. Nuclease constructs were purified from whole cell extracts by 
chromatography on Capto-S ion exchanger (GE Healthcare Biosciences, Uppsala, Sweden) 
equilibrated in 20 mM MES buffer pH 6.0 containing 6M Urea. Target protein was eluted by a NaCl 
concentration gradient, then further purified and desalted by RPLC on a 1 cm diameter C4 column 
(Vydac, Hesperia, CA) operated with trifluoroacetic acid, water, acetonitrile mobile phases.  
GST constructs were purified on immobilized glutathione purchased from GE Healthcare and operated 
according to recommendations of the support manufacturer. Product was further purified and desalted 
by RPLC performed as above. Purified proteins were recovered in dried form using a Speed Vac 
apparatus (Savant Instruments, Holbrook, NY) 
 
Preparation and screening of the VHH library 
The camel immunization protocol followed the animal experimentation guidelines published by the 
Regional Canary Government and was approved by the Ethic Commission of the Veterinary Faculty, 
University of Las Palmas. 1 mg of each antigen (4 different proteins, see table 1) was injected 
subcutaneously once a week for 5 consecutive weeks. Complete Freund's adjuvant was used for the 
first injection and incomplete Freund’s adjuvant for the following injections. Then a period of three 
weeks without immunisation was taken before the animal received two boost injections at one week 
interval. Blood was taken on EDTA anticoagulating medium one week after the last boost. 
Construction of the VHH library followed well-established steps [48-52 and references cited therein]. 
Lymphocytes were isolated from dromedary’s blood and cDNA was prepared. DNA fragments coding 
for VH (present in conventional antibodies) and VHH (present in heavy chain-only antibodies) were 
amplified using a suitable primer pair. DNA fragments encoding the VHHs were purified on a 
preparative agarose gel and re-amplified by nested PCR. The amplicons of the second PCR were 
ligated into pHEN4 phagemid vector. DNA present in plasmid encodes the VHH followed by a 
hemagglutinin tag, an amber stop codon and the g3 protein from M13 phage. Expression in permissive 
TG1 cells in presence of helper phage M13KO7 produces bacteriophage particles that display the 
VHH at their tip. In absence of helper phage, VHH may be recovered from a periplasmic extract of 
TG1 cells. The VHH library expressed on phage particles was screened for binders to ECD1-GST 
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constructs with wild type Fya and Fyb sequences coated on ELISA plates. Antigen recognition by 
VHH from the periplasmic extracts of isolated clones was evaluated by ELISA.  
 
Subcloning, expression and purification of VHH  
VHHs were subcloned in a vector named pHEN6cPm derived from already described plasmids. 
Translation product contains the PelB-leader sequence, the VHH sequence, HA tag and finally a six 
His sequence. Expression of the VHH was done using TB medium (1 litre) and fermentation left to 
proceed from 14 to 20 hours at 28°C after isopropyl thiogalactoside induction. Periplasmic extract was 
prepared by osmotic schock and VHH purified using a 10 ml Nickel-loaded His-select column (Sigma, 
L'isle d'Abeau, France). The VHH concentration was calculated from the absorbance measurement at 
280 nm using extinction coefficient computed on Expasy website (http://www.expasy.ch/tools/). 
 
SDS-PAGE and western blotting  
SDS-PAGE was performed in continuous 15% acrylamide minigels cast in Novex (Invitrogen 
Carlsbad CA) cassettes. Gels were stained either with Coomassie Brilliant Blue or silver nitrate as 
indicated in legends to figures. 
Blotting onto nitrocellulose membranes was performed in the semidry apparatus from Novex. The 
antibodies used were: (i) CA52 VHH (1 µg/ml) (ii) anti-HA antibody (Clone 16B12) purchased as 
ascitic fluid from Covance (Emeryville CA) at 1/1000 dilution; (iii) 2C3, an anti Fy6 antibody 
(1µg/ml) [6]; (iv) an anti Staphylococcus aureus nuclease rabbit antiserum developed in house and 
diluted 1/2000; (v) as needed peroxidase conjugated anti mouse or anti rabbit antibodies (antisera from 
P.A.R.I.S., Compiègne, France) diluted 1/800. Solution for diluting antibodies was Tris buffered saline 
containing 5% skimmed milk. Incubations with the different antibodies were performed overnight at 
4°C or 1 hour at 37°C. Washings were in Tris buffered saline supplemented with 0.5 % (v/v) Tween 
20. The ECL kit (GE Healthcare Biosciences) was used according to the manufacturer’s 
recommendations for chemiluminescent detection of the primary antibodies.  
 
Epitope mapping by western blots of ECD1 deletion constructs and synthetic peptides on plastic 
pins 
Western blot using ECD1 deletion mutants was used as a preliminary and fast specificity screen of 
VHH. More precise identification of the epitope recognized by CA52 was performed using synthetic 
peptides grafted at the tip of plastic pins. The epitope scanning kit was purchased from Chiron 
Mimotopes (Clayton, Victoria, Australia). The syntheses were done by stepwise elongation of the 
peptides from C- to N-terminus, following the manufacturer’s instructions. A set of octapeptides 
covering the sequence of amino acids 17-30 of the Duffy ECD1 and 95 analogues of pentapeptide 
FEDVW were synthesized. Binding of purified CA52 VHH to immobilized peptides was determined 
by an enzyme-linked immunosorbent assay as described earlier [6]. Briefly, the pins arranged 
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according to the format of a 96-well microtiter plate [55] were blocked by immersing in 2% BSA, in 
TTBS (0.1% Tween-20 in Tris buffered saline) contained in wells of an ELISA plate (200 µl/well) and 
incubating for 2 hours at room temperature. The pins were subsequently incubated in wells containing 
150μl of: CA52 (50 ng/ml in TTBS, overnight, 4°C), anti-HA mouse monoclonal antibody (purified 
antibody, clone 16B9 Covance, 0.5 μg/ml in TTBS, 1 hour, room temperature) and alkaline 
phosphatase-conjugated rabbit anti-mouse IgG (Dako, 1500-times diluted in TTBS, 1 hour, room 
temperature). After each step the pins and the wells were washed 5 times in TTBS. Color reaction was 
developed with phosphatase substrate tablets (Sigma). The absorbance was measured at 405 nm in a 
microtiter plate reader. The peptides, except those for replacement analysis, were synthesized at least 
in duplicate and the results are mean values of at least two ELISA tests. Reaction with anti-HA 
antibody and tagged anti mouse alone was determined as a control and gave low optical density 
values. Final results (presented in figure 2) are differences of readings obtained with CA52 followed 
by anti-HA and tagged anti-mouse antibodies and those obtained with only anti-HA followed by 
tagged anti-mouse.  
 
In silico studies: proposition of pertinent VHH structural models  
Structural templates have been searched with PSI-BLAST software [56]. Two VHH protein structures 
extracted from the Protein Data Bank [57] were used as templates to build the structural models (PDB 
codes: 1JTO [58] and 1OP9 [59]). The protein sequences have been aligned with Clustalw2 software 
[60] including minor additional manual changes. The comparative modelling has been performed with 
the Modeller software [61]. The disulfide bond between residue 33 and 107 has been constrained. 200 
independent structural models were produced and compared after superimposition with ProFit 
software (http://www.bioinf.org.uk/software/profit/). The mean structural model has been selected 
based on root mean square deviation values between the structural models. Its topology was checked 
using ProCheck software [62].  
 
Binding kinetics of VHH to its ligands 
Surface plasmon resonance (SPR) evaluation of kinetic rate constants of binding of VHH to its target 
on ECD1 has been performed in a Biacore X100 instrument (GE Healthcare). Two kinds of ligands 
were used, one was wild type ECD1 nuclease fusion construct (table 2), the other was full size 
recombinant DARC purified from engineered K562 cells (see below details on purification) ; prior to 
immobilization DARC was dialyzed in Pierce cassettes -Rockford IL- to 10 mM HEPES buffer pH 7.4 
buffer containing 0.3% C12E9 detergent, (Sigma). Ligands were immobilized on the analysis Fc2 
channel of CM5 chips using NHS (N-Hydroxysuccinimide) and EDC (1-[3-(Dimethylamino)-propyl]- 
3-ethylcarbodiimide hydrochloride) chemistry according to manufacturer's instructions. Wild-type 
nuclease has been immobilized on the reference channel when ECD1-nuclease construct was in Fc2 
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while dextran layer was simply activated and deactivated in the case of analysis with full length 
DARC.  
Amounts of immobilized proteins were kept low in order to be safe from mass transfer limitation 
artefacts.  
Concentrations of analyte (CA52) varied from 0.3 to 10 nM. Langmuir model for a 1:1 interaction was 
chosen to evaluate the data using manufacturer's software. 
To further analyze binding of CA52 to DARC experiments were performed also on in situ 
deglysocylated DARC performed as follows. Temperature of the instrument was set to 37°C and flow 
rate to 5 µl/min 5000 units of N-glycosidase (New England Biolabs, Ipswich, MA) were dissolved in 
reaction buffer and injected manually onto Fc2 three times consecutively for 1000 seconds each time. 
Deglycosylation was checked using Sambucus nigra lectin which is known to be retained by sugars 
terminated by sialic acid [63-64]. Lectin was injected at several concentrations from 7 to 70 nM before 
and after deglycosylation.  
 
Flow cytometry experiments  
Erythrocytes of the various phenotypes were obtained from the Centre National de Reference pour les 
Groupes Sanguins, (CNRGS, Paris). Red cells were washed twice in phosphate buffered saline (PBS). 
After the second wash, the cells were resuspended with either: (i) anti Fy6 murine monoclonal 
antibody 2C3 (culture supernatant diluted 1:8); (ii) isotype control antimurine IgG (5 µg/ml, Becton 
Dickinson, Franklin Lakes, NJ); (iii) periplasmic extract of TG1 cells producing CA52 diluted 1:2 in 
PBS/0.1% BSA; (iv) periplasmic extract of non transformed TG1 cells as control; or (v) purified 
CA52 (10 µg/ml). Suspension was let at room temperature for one hour. After primary incubation, 
VHH or periplasmic extract incubated cells were washed twice in wash buffer and incubated for one 
additional hour in presence of anti-HA monoclonal antibody (clone 16B9 as an ascitic fluid purchased 
from Covance, diluted 1:1000). A control of red blood cells incubated with anti-HA alone was also 
prepared. Cells were washed again before one hour incubation in the dark at room temperature with 
antimurine phycoerythrin(PE)-tagged antibody (Beckman Coulter, Villepinte, France) (5 µg/ml in 
PBS/0.1% BSA solution). The 2C3-treated and control cells were handled in parallel. After a final 
wash step in PBS, cells were analyzed by digital high speed analytical flow cytometry. Erythrocytes 
were identified based on forward and side scatter characteristics using logarithmic amplification. 
Excitation wavelength was 488 nm, PE signal was collected with a 585/42 band pass filter. Data were 
acquired by BD FACS Diva software (v6.1.2), and analyzed using FlowJo (Treestar, Ashland, OR) 
software v7.2.5.  
Flow cytometry was also used to characterize DARC expressing recombinant K562 cells [66]. Qifikit 
(Dako France Trappes) was used to measure binding sites number per cell.  
 
Agglutination studies  
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In order to perform the agglutination studies, either: (i) crude periplasmic extract diluted 1:2 in PBS; 
(ii) purified VHH dissolved at 10 µg/ml concentration in PBS and serial two-fold dilutions; or (iii) 
purified 2C3 (10 µg/ml and serial two-fold dilutions) were incubated at room temperature with red 
blood cells from defined phenotypes obtained from CNRGS (Paris, France). Volume of suspension 
was 40 µl, hematocrit was 4%. After 60 minutes of incubation at room temperature 20 µl of PBS 
containing anti-HA antibody (ascitic fluid Covance final dilution 1/100) were added to the VHH 
containing tubes and PBS to the 2C3-containing tubes. Incubation was let to proceed for a further 20 
minutes. Finally 20 µl of anti mouse IgG, raised in goat (P.A.R.I.S), diluted 1/100 in PBS were added, 
the suspension was incubated for 20 minutes. 40 µl of the suspension were loaded on top of the 
Diamed (Cressier, Switzerland) column, which was then operated as recommended by the 
manufacturer. Controls with only anti-HA followed by anti mouse IgG, and only anti-mouse IgG were 
also prepared and analyzed likewise.  
 
Study of the inhibitory effect of CA52 on red cells invasion by P. vivax 
This study was approved by the Committee on Human Rights Related to Human Experimentation, 
Mahidol University, Bangkok, MU-IRB 2009/133.2306. Inhibitory effect of CA52 on red cells 
invasion by P. vivax was evaluated using short term culture conditions as described before [67]. Red 
blood cells naturally infected with P. vivax parasites were obtained from three volunteers living in 
Mae Sot, Tak province, Thailand. Informed consent was obtained from each volunteer before the 
blood collection was performed. Heparin was used as anticoagulant. Leukocytes were removed from 
the blood by filtration through Plasmodipur® filter (Chemicon, Millipore) and red blood cells were 
washed with McCoy’s medium to remove plasma and heparin. CA52 was incubated with the P. vivax-
infected blood for 2 hours at 37oC at 25µg/ml final concentration to allow saturation binding of CA52 
on the red blood cell membrane. At the end of 2nd hour, the excess of CA52 was removed by washing 
the red blood cells with McCoy’s medium twice at room temperature. The red blood cells were 
reconstituted to 2% cell suspension with McCoy’s medium containing 30% heat-inactivated human 
AB serum and incubated for 24 hours under the in vitro malaria culture conditions. Thin blood films 
were prepared at the end of incubation time and numbers of infected red blood cells at various stages, 
i.e. ring, amoeboid, schizont, gametocyte and free merozoite, were enumerated under microscope (100 
X oil immersion). Numbers of parasites at various stages are expressed relative to 104 erythrocytes 
(Table 3).  
An anti lysozyme VHH (D3L11 [68]) was used and processed in the assay similarly to CA52, 
moreover culture medium without VHH addition was used as a control of parasite invasion under the 
conditions used for the test.  
 
Displacement of interleukin-8 bound to red blood cells by VHH 
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The interleukin-8 (IL8) binding studies were performed essentially as described [66]. Eppendorf tubes, 
each containing 108 red cells washed in PBS were incubated with 125I labelled IL8 (specific activity 
2200 Ci/millimole, Perkin Elmer, Boston, MA) at 0.3 nM final concentration in a final volume of 100 
µl PBS containing 1% w:v of Bovine Serum Albumin (PBS-BSA). All data points have been obtained 
in triplicate. Most of collected data points concerned Fy(a+b+) red cells but some were controls with 
Fy(a-b-) red cells obtained through CNRGS. Three tubes were prepared in which cold IL8 (Peprotech 
Rocky Hill, NJ) at 200 nM final concentration had been added together with radioactive cytokine. 
After incubation, the tube contents were transferred in long and narrow 0.5 ml centrifuge tubes 
containing 180 µl of a 85:15 mixture of DC550 silicon oil (Serva ref 35145) and Nujol oil (Alfa 
Aesar). They were centrifuged at 4000 rpm for 20 seconds. Cell pellets were dissolved in 100 µl 
dimethylsulfoxide and radioactivity counted in a Packard Tri Carb liquid scintillator. All obtained 
count numbers were subtracted by the background counts measured for tubes containing cold IL8.  
 
Preparation of immobilized CA52 
10 mg CA52 was brought to 0.2 M sodium carbonate pH 8.5 containing 0.5 M NaCl using a 
Millipore-Amicon ULTRA-15 centrifugal device fitted with a 5000 Da molecular weight cut off 
membrane. The VHH solution was then recirculated overnight in the cold room into a Hitrap 1 ml N-
hydroxy succinimide activated column (GE Healthcare) prepared according to the manufacturer's 
recommendation. After that, the column was rinsed with ethanolamine in order to de-activate the 
potentially remaining reactive groups.  
The column was then dismantled to allow to recover the gel which was pushed out with a syringe into 
a test tube. 
 
Purification of DARC on immobilized VHH 
Transfected K562 cells expressing DARC wild type sequence have been described [66]. They were 
grown at 37°C, 5% CO2 in Dulbecco’s modified Eagle’s medium-Glutamax I (GIBCO, Invitrogen 
Carlsbad, CA) supplemented with 10% foetal calf serum and 0.8 mg/ml geneticin. A 1 liter Lampire 
bag (with gas permeable walls and a cap fitted with Luer ports; (Lampire, Pipersville, PA)) was used 
for cell cultivation. Cell density was maintained between 350 000 and 700 000 cells/ml and 500 ml of 
cell suspension harvested once a week, and replaced with fresh medium. Cells were recovered by 
centrifugations, and frozen in aliquots till purification. 
Starting material for purification was a frozen pellet corresponding to 150 106 cells. Pellet was thawed 
and suspended in 40 ml of lysis buffer (20 mM Tris-HCl pH 8.0, 0.15 M NaCl, 5 mM EDTA, 
1%Triton X100, and a cocktail of protease inhibitors from Roche, Basel, Switzerland). The suspension 
was incubated at 4°C, with gentle agitation, for one hour. The tubes were centrifuged for one hour at 
72600 g in a Beckman 25.5 rotor.  
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The affinity gel (200 µl) with the immobilized CA52, prepared as described above was equilibrated 
with the lysis buffer. Gel and cell lysate supernatant were mixed and incubated overnight in the cold 
room, with gentle agitation. The suspension was centrifuged at 12000 g for 8 minutes. Gel was washed 
by centrifugation once with the lysis buffer and then twice with wash buffer (150 mM NaCl, 10 mM 
Tris 20 mM NaCl 5 mM EDTA (pH 7.6) containing 0.3% octaethylene glycol monododecyl ether 
(C12E8). The gel was transferred to an Amicon Ultrafree MC 500 µl filter unit (Millipore Saint Quentin 
en Yvelines, France) fitted with a 0.5 µm pore size membrane. Then 100 µl of wash buffer plus 1% 
glycerol and 2.5 mg of DFEDVW synthetic peptide (Polypeptide Laboratories, Strasbourg, France) 
was added to the sedimented gel in the filtration cup. The suspension was gently agitated at room 
temperature for 4 hours, the cup placed on top of an Eppendorf tube and centrifuged for 2 minutes at 
1000 g. Peptide elution was repeated three times but lowering incubation time before centrifugation to 
30 minutes. Finally gel was washed twice with buffer without peptide and then treated with 0.1M 
Glycine pH 2.8 buffer, recovering filtrates by centrifugation as above. All recovered fractions were 
analyzed by SDS PAGE and western blotting. Purified material was also digested by N-glycosidase 
according to recommendations of the supplier of the enzyme (New England Biolabs).  
 
 
RESULTS 
 
Construction of VHH library, retrieval and purification of VHH-CA52 
The VHHs from circulating lymphocytes of the dromedary immunized with ECD1 fusion protein were 
cloned in a library of 7.5 x 108 independent colonies of which 80 % contains an insert in the phagemid 
with a size that corresponds to that of a VHH. After phage display and panning on ECD1 GST, 28 
VHHs that recognized the antigen specifically were identified. The VHH referred to as CA52 which is 
the subject of this report was found 8 times among these colonies. 
Repeated expression of CA52 yielded after purification on the nickel column between 1.0 to 2.5 mg 
protein per litre of fermentation medium. Figure 1 (panel A) illustrates the purity of the final product 
on SDS-PAGE and western blot. 
 
Epitope mapping of CA52 by western blots of ECD1 deletion constructs and synthetic peptides 
on plastic pins 
Western blots of the ECD-1 deletion constructs probed with CA52 are shown in Figure 1 (panel B). 
All deletion constructs are recognised by the CA52, except deletions II and III. This result is similar to 
that obtained for the monoclonal anti-Fy6 murine antibody 2C3. The control with antinuclease 
antiserum demonstrates that all lanes have been loaded with the same amount of antigen. The 
antinuclease antiserum reveals two bands in the deletion I preparation (lane 2 of Figure 1B). The lower 
band (having the nuclease tag) is a proteolysed fragment that deletes the 2C3 and CA52 epitope. From 
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all these data we propose that the CA52 epitope should encompass the ECD1 sequence 
QLDFEDVWNSSYGVND. 
Peptides synthesized on plastic pins were used to identify the amino acids of ECD1 that are important 
for CA52 recognition. The octapeptides of the ECD1 sequence that react with CA52 exhibit a very 
similar reactivity to those described for 2C3: the FEDVW peptide sequence is the linear epitope of 
CA52. Lengthening this sequence to either end does not change the reactivity to a great extent (Figure 
2 panel A). Panels B to F show the effect of individual substitutions for each amino acid of the 
sequence by the 19 other amino acids. Again, one may appreciate the close similarity between the 
CA52 and the 2C3 association with the various peptides. We will elaborate more on the minor 
differences between the CA52 and murine 2C3 in the discussion section. 
In silico experiments of CA52 structure  
A pertinent structural model of CA52 VHH has been proposed through a classical comparative 
modelling approach. The chosen VHH structural templates (1OP9 and 1TO) share 75% of sequence 
identity with CA52. As VHH specificities are mainly determined by the three complementarity 
determining regions (CDR1, CDR2 and CDR3), these regions received particular attention. The first 
structural template (1OP9) has been selected since it possesses a good compatibility with CA52 for its 
length and amino acid composition within CDR1 and CDR2. Moreover, in addition to the 
characteristic disulfide bond present in immunoglobulin domains linking B and F -sheets, 1OP9 has 
an extra disulfide bond linking CDR1 and CDR3 frequently present in dromedaries' VHHS [70] : 
likewise CA52 has a pair of cysteines at  residues 33 and 107. The second structural template (1JTO) 
has also a good similarity for CDR2 and CDR3, but it lacks the interloop disulfide bond. Figure 3A 
shows the alignment of the amino acid sequences of CA52, and the 1JTO or 1OP9 VHHs; the CDRs 
and the disulfide bonds are also indicated.  
Differences between the generated structural models are limited (average value of root mean square 
deviations between models is 0.45 Å, its maximum goes to 2.5 Å). This peculiarly limited variability 
is mainly due to the 4 framework regions of VHH which are structurally very well conserved in all 
VHHs, and to the disulfide bridge linking CDR1 and CDR3 which strongly constraints the CDRs. 
Figure 3B shows two representations of the selected structural model, each seen from two view angles: 
left as cartoons and right with a colour coded electrostatics surface. The first representation gives a 
good view of the position of CDRs forming a continuous surface at one side of the VHH. The second 
representation illustrates the charge distribution on the surface. The CDR1 and CDR3 and the central 
part of CDR2 present a strong positive charge (blue colour) whilst only extremities of CDR2 are 
negative (red colour). This peculiar charge distribution observed on CA52 surface is absent on the two 
structural templates. From crystal structures of other VHHs in complex with their cognate antigens it 
is known that CDR3 is the major contributor for the antigen recognition [44]. The presence of positive 
charges in this area and the presence of negative charges in the linear target peptide are suggestive for 
important ionic interactions. 
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Kinetic binding analysis of CA52 ECD-1 interaction 
A SPR sensorgram acquired using ECD1-Nuclease construct as ligand is shown in Figure 4. The fitted 
kinetic data derived from it are given in Table 2. The kinetic analysis reveals that indeed the affinity of 
CA52 is very high with a computed KD of 2.38 x 10
-10 M. This high affinity is attained largely by an 
extremely fast association rate constant of 2.31 x 107 M-1s-1. With DARC purified from eukaryotic 
cells, instead of recombinant prokaryotic ECD1-Nuclease construct a similar KD was obtained (2.59 x 
10-10 M) but ka and kd were somewhat lower (Table 2). Deglycosylation of immobilized DARC 
brought kinetic constants close to those observed with prokaryotic construct. Efficient deglycosylation 
through N-glycosidase was suggested by a baseline signal drop after enzymatic treatment, it was 
proven by the absence of binding of Sambucus nigra lectin after deglycosylation contrasting to 
definite binding before deglycosylation.  
 
Flow cytometry and agglutination studies 
We assessed the possible recognition of the native DARC epitope on red blood cells by CA52 by flow 
cytometry and agglutination tests. The results of the flow cytometry (Figure 5) clearly proves that 
CA52 recognizes Duffy antigen positive red cells independently of the actual allotypes present on the 
red blood cell surface (panels D to F) and fails to interact with the Fy(a-b-) cells (panel C). Additional 
experiments show that the anti hemagglutin antibody - used as an auxiliary antibody for CA52 
detection - does not react appreciably with red cells (panel G). As expected 2C3 reacts with Fy(a+b+) 
cells (panel B) and not with Fy(a-b-)(panel A). 
Panels H and I in Figure 5 show that flow cytometry can be used to detect the presence of cell-specific 
VHH in a periplasmic extract prepared in the conditions used for library screening (panel I) while 
similar periplasmic extract of non transformed TG1 bacteria fails to react with red cells (panel H).  
 
Agglutination experiments performed with purified CA52 at concentrations of 10 and 5 µg/ml 
exhibited a positive reaction (+++ according to the Diamed scoring criteria), provided that anti-HA 
antibody and anti mouse IgG were present in the assay. Negative reactions were obtained for higher 
dilutions of CA52.  
Agglutination was also observed (++) with crude periplasmic extract from CA52 transformed cells but 
not from non transformed cells. As controls, agglutination was also performed with 2C3: murine 2C3 
monoclonal in combination with an anti mouse IgG shows a zone effect in the agglutination of red 
blood cells with no agglutination at 10 µg/ml, ++ agglutination at 5 µg/ml, +++ reaction from 2.5 to 
0.16 µg/ml and ++ at 0.08 µg/ml.  
 
Modulation of DARC function by CA52 
1. CA52 prevents Plasmodium vivax red blood cell invasion.  
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Inhibitory activity of CA52 on the merozoite invasion of red blood cells was determined using three 
clinical P.vivax isolates. The parasites co-cultivated with CA52 showed significant reduction of the 
number of infected red blood cells compared with those in the cultivation without VHH or with 
control VHH, i.e. an anti-lysozyme VHH. CA52 does inhibit strongly merozoite invasion in all three 
isolates (see Table 3). Obviously these results should be confirmed on a larger number of isolates 
taken at several places of endemicity.  
2. Displacement of IL8 bound to Fy(a+b+) red cells by CA52.  
The interference of CA52 with IL8 binding on DARC was evaluated in competition experiments. 
Figure 6 reveals that CA52, even at low nanomolar concentrations, competes effectively with IL8 for 
binding to Fy(a+b+) red blood cells. The2C3 is also effective under these conditions whereas controls 
including anti lysozyme VHH and non relevant IgG are without any effect. No binding of IL8 to Fy(a-
b-) red blood cells is observed, as expected.  
 
Immunoaffinity purification of DARC on immobilized CA52  
Preliminary tests indicated that CA52 (in presence of anti-HA antibody) was able to 
immunoprecipitate DARC from red cells membrane extract. This suggested that CA52 might be used 
to immunopurify DARC. We used transfected K562 cells as starting material. DARC is expressed at a 
density of ca. 35000 sites/cell. Figure 7 demonstrates that immobilized CA52 is indeed able to 
immunocapture DARC satisfactorily and that this antigen is efficiently eluted by a synthetic 
hexapeptide containing the epitope sequence. As expected, DARC appears on the silver nitrate stained 
gel as a smear from 45 to 55 kDa. This corresponds quite well to what is usually observed in red cell 
lysate after western blotting. A prominent band is also visualised at ca. 90 kDa which is obviously a 
dimer of DARC, and bands which barely migrate into the gel are probably higher oligomers. The 
DARC-nature of all these bands is confirmed by (i) western blot probed with 2C3, (ii) the lowered 
apparent molecular mass of monomer, dimer and oligomers after N-glycosidase treatment. Two extra 
bands are also discerned on the silver nitrate stained gels: one corresponding to the VHH that leaks 
from the immunoaffinity support (arrow 1 on Figure 7 panel A), and an unidentified protein (arrow 2 
on Figure 7 panel A). 
 
DISCUSSION  
 
To the best of our knowledge, this report is the first description of the preparation of recombinant 
antibodies derived from an immunized dromedary and specific for a blood group protein. It is a further 
proof that VHHs provide powerful tools for purification of membrane proteins [49] and for the 
modulation of the biological function of their targets in absence of the Fc effector function.  
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The antigen we used for the immunization of the dromedary and screening of the library was a 
recombinant derivative of the target protein produced in E. coli. Only part of the molecule, i.e. DARC 
ECD1 (fused with nuclease), was injected into the animal and numerous antibodies were elicited. We 
have not yet studied the detailed specificities towards DARC of all the retrieved VHHs but several 
were shown to react specifically with Fy(a+b+) red blood cells. This point is of importance since 
DARC is known to be N-glycosylated on the three available sites on ECD1 (N16, N27 and N33) [65], 
so that epitopes on the non glycosylated E.coli produced recombinant protein might be cryptic in the 
glycosylated DARC present on red blood cells. Reactivity of our VHH CA52 with red blood cells was 
evidenced by flow cytometry as well as by agglutination techniques. An equal reactivity of CA52 was 
observed for cells expressing either Fya or Fyb allotypes. 
The CA52 recognizes the same linear FEDVW epitope as the murine 2C3 monoclonal, a reference 
antibody for the Fy6 antigen [6]. Nevertheless there are some notable differences regarding the 
detailed specificities of 2C3 and CA52. In the FEDVW oligopeptide, F cannot be replaced by any 
other residue for both CA52 and 2C3, whereas E can be substituted by several amino acids without 
abolishing the binding of CA52. Surprisingly, E can be replaced in the peptide by W, Y, and H to give 
a binding of respectively 180%, 100 %, and 130% to the level observed with E. By contrast, for 2C3, 
E can be replaced by D and N only. That E might be exchanged by an aromatic residue in the epitope 
recognized by CA52 suggests that the paratope is probably engaged in either a purely ionic interaction 
or in cation-Pi interactions [69] when challenged in the synthetic peptide with an aromatic amino acid 
at this position. For CA52, the D in the epitope can be freely substituted by nearly any amino acid 
except by P, likewise, 2C3 is also tolerant to substitutions at this position. The V residue can be 
replaced by hydrophobic aliphatic residue I with retention of CA52 interaction, while it cannot be 
replaced by any other residue in the case of 2C3. The W26 is mandatory for recognition by 2C3 
whereas this residue in the peptide may be changed to an F or hydrophobic M in the case of CA52.  
These CA52 binding results on target peptide variants are in line with the current structural model of 
CA52. The structural model reveals the presence of a large patch of basic side chains on paratope face 
of the VHH which are likely to participate in interactions with acidic and aromatic residues on the 
epitope. 
The SPR results of affinity measurements reveal a subnanomolar equilibrium dissociation constant for 
CA52 on DARC, a value that is most favourable for future diagnostic or therapeutic applications. 
Worth of notice, glycosylation of DARC exerts some influence on kinetic constants since ka and kd 
measured on glycosylated DARC are lower compared to values with prokaryotic construct as ligand 
(but KD with both ligands, E. coli expressed ECD1 and K562 expressed DARC is in the 10
-10 range). 
Enzymatic deglycosylation of DARC, does increase ka to value similar to that of the E. coli produced 
ligand. It is interesting to note that enzymatic modification of ligand could be easily performed in the 
Biacore instrument. 
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Importantly, CA52 inhibits two well identified biological functions of DARC, the IL8 binding, and the 
invasion of red blood cells by P. vivax merozoites. DARC plays a critical role in a wide range of 
diseases, including malaria where DARC has been identified as the main receptor for the parasite, 
even though its precise molecular interactions with Plasmodium vivax duffy binding protein (PvDBP) 
remain elusive. Our results establish that CA52 inhibits P. vivax merozoite red blood cell invasion. It 
is surmised that the inhibitory effect of CA52 is caused by a steric hindrance: binding of CA52 to its 
cognate ECD1 target precludes binding of PvDBP at the same or overlapping site. Previous studies 
using ECD1-GST fusions and PvDBP confirmed that the sequence recognized by 2C3 (and now CA52 
as well) were important to PvDBP binding [13]. 
An obvious suggestion would be to design a therapeutic agent, taking the CA52 as a lead, to prevent 
the invasion of human red blood cells by P.vivax, indeed it has been already suggested that Duffy 
antigen inhibitors might be useful therapeutic agents for P. vivax malaria [71]. However, recent data 
suggest that P.vivax has shortcut its absolute dependency on DARC to invade red blood cells [19-21], 
even if it is still believed to be the main entry route, as suggested by the inverse correlation of P. vivax 
malaria severity with expression level of DARC on red cells [72-73]. One can observe mixed 
infections with more than one species of Plasmodium in one single individual; coexistence of diverse 
Plasmodium species infecting populations living in the same area is also frequently encountered. All 
this pinpoints the need of quick, reliable, sensitive techniques for diagnostic of malaria causative 
species (ideally applicable also in remote and poor areas [74]). Lastly, if a drug targeting DARC was 
designed it should be carefully checked that it does not interfere with the normal functions of DARC 
which presently are not yet fully understood. In this regard it may be noted that DARC plays a role in 
the equilibrium of the chemokine-chemokine receptor network implicated in many diseases, including 
cancer and inflammatory diseases [27-35]. CA52 might help to understand role of DARC in disease. 
Our results showing the effective displacement of IL8 from DARC by CA52 are in this regard highly 
relevant. Worth to notice chemokines and chemokines receptors, despite complexities and 
redundancies, are targets for present days' pharmaceutical research and some successes have been met 
[reviews in 75-76]. 
 
Similar to what has been observed with P.vivax infection, it will be interesting to investigate the 
possibility of CA52 to preclude binding of HIV to DARC-positive red blood cells [39] keeping in 
mind that, presently, experimental data on binding of HIV to red cells and the relation of this binding 
with HIV infection and AIDS progression seems to be complex and controversial [39-45].  
 
The CA52 is indeed an invaluable tool for DARC purification. At present, our results involve only 
small scale experiments, but apparent yield and purity are sufficiently promising to switch to more 
ambitious studies, e.g. aiming to crystallize DARC. In this regard, it should be mentioned that VHHs 
have been proposed as a versatile tool to aid the crystallization of proteins [50]. The CA52 purified 
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DARC, appears as multimers on our gels, while it is usually present as a monomer when analyzed 
through western blot in red blood cells membrane lysate. Indeed, it has been indicated that in cell 
lines, multimer formation was likely to occur and this form might even participate to DARC function 
(at least in other cells than red blood cells) [35]. Presence of oligomers of membrane proteins on SDS 
gels is in fact rather common and it was shown in several occasions that multimers formation might be 
correlated to concentration in sample [77], definitely higher in purified material compared to that 
present in red cells.  
Purification of membrane proteins is notoriously difficult. Expression level of target protein in starting 
material is indeed an important factor to the success [78]. DARC expression level in our recombinant 
K562 cells is far from the one reached by others : e.g. poly his tagged D6 was purified from 
engineered cells efficiently on immobilized metal but copy number was more than 20 fold higher than 
ours [79].  
Immunoaffinity chromatography on a high affinity antibody provides a powerful and elegant method 
for the facile recovery of membrane proteins even when they are present at a relatively low 
concentration in starting material. Common practice when using affinity chromatography is to use 
harsh eluting solutions like pH jump or "deforming" mobile phases which may denature target protein. 
Elution through epitope peptide is likely to maintain native conformation. Tagging proteins with short 
linear epitopes has been used as a shortcut to immunopurify membrane proteins when no convenient 
antibody was available [80-82]. However introduction of a foreign peptide tag may be deleterious to 
proper expression and/or function of the protein. Hence, as a (possibly) generally applicable strategy 
for purification of membrane proteins we propose: (i) to immunize a camelid with (easily expressed) 
E. coli recombinant proteins containing extra membranous loops of the target protein, (ii) to prepare 
and to screen the derived library to obtain VHHs (iii) finally, to prepare from selected VHHs, suitable 
immunoaffinity supports for purification of the target protein.  
The appeal of this strategy relies entirely on the peculiarly favorable properties of VHHs as stable, 
cheap, easily produced reagents. Its application to DARC, besides to be a proof of concept, is 
interesting since it should facilitate collecting data on this blood group protein, important in many 
devastating human diseases. 
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Table 1,   Sequences of constructs used in this study. 
 
 
Antigens used for 
immunization  
MATAVHRAELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYG/DANLEAAAPCHSCNLLDDSALPAAKK-(nuclease) 
MATAVHRAELSPSTENSSQLDFEDVWNSSEGVNDSFPDGDEG/DANLEAAAPCHSCNLLDDSALPAAKK-(nuclease) 
 
Antigens for library 
screening 
(GST)-GILGNCLHRAELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYG/DANLEAAAPCHSCNLLDDSASSGRIVTD 
 
Deletion mutant I MATAV---------ENSSQLDFEDVWNSSYGVNDSFPDGDYGANLEAAAPCHSCNLLDDSALPAAKK-(nuclease) 
Deletion mutant II MATAVHRAELSPSTENSS------------GVNDSFPDGDYGANLEAAAPCHSCNLLDDSALPAAKK-(nuclease) 
Deletion mutant III MATAVHRAELSPSTENSSQLDFEDV---------SFPDGDYGANLEAAAPCHSCNLLDDSALPAAKK-(nuclease) 
Deletion mutant IV MATAVHRAELSPSTENSSQLDFEDVWNSSYGVND------------AAAPCHSCNLLDDSALPAAKK-(nuclease) 
Deletion mutant V MATAVHRAELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYGANLEAAAP----------ALPAAKK-(nuclease) 
 
Residues which belong to the first extracellular domain of DARC are underlined, other residues belong either to the fusion partner (indicated in parentheses) or are flanking residues 
which were introduced through the construction of the plasmid. A larger font is used to show the allotypic variants (either G or D at position 42 of ECD1). Positions of mutants of Y 
to E at positions 30 and 41 are shown with a larger and bold font. ((GST) is the abbreviation for Glutathione S-transferase)  
 
Table 2,  Kinetic rate constants measured in the Biacore X100 instrument and the equilibrium dissociation constants derived from them. 
 
Ligand ka (M-1s-1) kd   (s-1) KD  (M) 
Prokaryotic construct 2.31 107 5.49 10-3 2.38 10-10 
DARC from K562 cells 5.78 106 1.50 10-3 2.59 10-10 
DARC from K562 cells after 
in situ deglycosylation 
2.28 107 2.39 10-3  1.05 10-10 
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Table 3,  In vitro merozoite infection assay 
 
 
Sample 
code 
VHH/controls Ringsa Amoeboidsa Schizontsa Gametocytesa Free 
merozoitesa 
Total 
parasitesb 
 
PV1 CA52 1.5 0 0 0.5 1.0 2 
D3L11 5 1.5 1 0 1 7.5 
Complete 
medium 
(control ) 
5.8 0.5 0.3 0.8 0.3 7.4 
 
PV2 CA52 0 0.5 0.5 0 1 1 
D3L11 0.5 0.5 4.0 0.5 0 5.5 
Complete 
medium 
(control ) 
1.0 0.5 2.5 0 0.5 4 
 
PV3 CA52 0 0 0 0 0 0 
D3L11 0 0 0.5 1.5 0 1.5 
Complete 
medium 
(control ) 
0.8 0.3 0.3 0.8 0 2.2 
aTotal number of parasites forms in 104 red blood cells, bFree merozoites are excluded 
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Legands to Figures 
 
Figure 1 
VHH purification and antigen-specificity screening  
Panel A ,  Expression and purification of CA52 VHH. The Coomassie Blue stained gel (CBB) 
contains molecular mass standards (lane 1, size in kDa are indicated), lysed bacterial pellet taken at the 
end of the fermentation (lane 2); the periplasmic extract from harvested bacteria (lane 3) and an 
aliquot of the purified material (lane 4). western blot was probed with anti-HA antibody. Lanes 2, 3 
and 4 were loaded with same material as used for the CBB stained gel. 
 
Panel B are three western blots using 2C3, CA52, and antinuclease antiserum as primary antibody. 
Samples in lanes 1 contain wild type ECD-1 nuclease fusion while lanes 2 to 6 contain the deletion 
mutants (I to V, see Table 1 for sequences of the deletion mutants).  
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Figure 2,   
Pepscan analysis of CA52 reactivity. 
Panel A shows binding of CA52 to octapeptides overlapping the DARC ECD-1 sequence from Ser 17 
to Tyr 30. Binding of CA52 was detected using anti-HA antibody as described in Methods and the 
final plotted value (measured after incubation with successively CA52, anti-HA and peroxydase 
tagged anti mouse antibody) was substracted by the signal value observed in a separate experiment 
with only anti-HA and peroxydase tagged anti mouse antibody.  
Panels B to F show the results of replacement analysis. Analogs of the pentapeptide FEDVW were 
used in which each amino acid was replaced with 19 other residues. They were tested for binding to 
CA52 (solid bars). Position of changed aminoacid in the pentapeptide sequence is shown by the 
question mark at top of each panel. Optical density values have been corrected for background signals 
from reaction values observed with only anti-HA and peroxydase tagged anti mouse antibody. The 
100% value is the absorbance value obtained with the wild type sequence. For comparison purposes 
values observed with anti Fy6 murine antibody 2C3 [5] are shown also on the histograms (hatched 
bars).  
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Figure 3 
Homology modelling of CA52  
Panel A is the alignment of CA52 with the two templates used for comparative modelling. Identity is 
indicated by stars and conservative replacements by colons under the sequences. Complementarity 
determining regions are boxed and disulfide bonds are indicated by grey and orange lines (grey is for 
the disulfide bond common to all immunoglobulin domains, orange is for the extra SS bond found 
frequently in dromedaries' VHHs, linking CDR1 and CDR3).  
Panel B represents the selected model viewed from two different viewpoints, the top representation is 
from an antigen-eye view, while for the lower one, we rotated the molecule by 90° over a vertical axis. 
The left is a cartoon representation of the model, the right shows the electrostatic surface distribution 
with basic area (blue) concentrated at the three CDR’s. 
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Figure 4  
Surface Plasmon Resonance analysis of CA52 interaction with the ECD-1 nuclease construct 
Sensorgrams obtained with the Biacore X100 apparatus using CA52 as analyte. ECD-1 fused to 
nuclease was immobilised on Fc2, the reference channel (Fc1) contained the nuclease. The highest 
concentration of CA52 was 10 nM and 4 two-fold serial dilutions were also injected. Coloured curves 
are experimental and black lines correspond to the fitted kinetic values (Table 2).  
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Figure 5 
Flow cytometry of red blood cells.  
The red blood cells with phenotype as indicated (upper right corner of each panel) were incubated with 
the 2C3 monoclonal (panels A and B), or with the purified CA52 (panels C-F), or with crude CA52 
extract (panel I). The gray histograms (panels A to G) correspond to results obtained with primary 
antibodies as indicated at the bottom of each panel. Clear histograms show the signals obtained using 
non relevant murine IgG and phycoerythrin tagged anti murine IgG (panels A and B), or only the 
secondary anti-HA antibody and phycoerythrin tagged anti murine IgG (panels C to F). 
Panel G is a control from cells stained with anti-HA antibody and phycoerythrin tagged anti murine 
IgG (gray histogram), blank histogram in panel G show results obtained with non relevant murine IgG 
and phycoerythrin tagged anti murine IgG. 
Panel H and I are the results from cells stained with proteins from the periplasmic extract of cells 
expressing CA52 or mock transformed cells (NT TG1), respectively. Gray histogram is the specific 
signal while clear histogram was obtained with anti-HA and phycoerythrin tagged anti murine IgG.  
Numbers above the horizontal bars indicate the percentage of cells of greyed histograms which are 
reactive with the indicated antibody.  
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Figure 6 
Displacement of interleukin-8 from red cells by CA52  
Histograms showing that CA52 and 2C3 compete with radioactive interleukin-8 for binding to 
Fy(a+b+) red cells. Each bar is the mean of three determinations; error bars correspond to one standard 
deviation. Shown also are results obtained with controls : (i) neither anti-lysozyme VHH D3L11 nor 
irrelevant murine IgG interfere with interleukin-8 binding to Duffy positive cells (ii) Duffy negative 
cells do not bind appreciably interleukin-8. 
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Figure 7  
Purification of DARC from transfected K562 by CA52 affinity chromatography  
A lysate of the transfected K562 cells expressing DARC was loaded on a CA52 immuno adsorbent. 
Upper panel shows silver nitrate stained SDS-gels. Lanes 1 and 12 contain molecular weight standards 
(purified CA52 has been added). Lanes 2 to 4 contain aliquots of washings of the support performed 
after the sample loading. Lanes 5 to 7 contain aliquots of material eluted with a solution of a 
hexapeptide containing the epitope sequence, whereas lanes 8 to 10 contain aliquots of washings made 
after the elution with peptide. Lane 11 contains an aliquot of acidic eluate from immobilized CA52 
gel. Lane 13 contains an aliquot of purified DARC, lane 14 contains an aliquot of purified DARC after 
treatment with N-glycosidase, and lane 15 contains the N-glycosidase, as a control. Arrowheads 1 and 
2 indicate the positions of CA52 leaked from the adsorbent and an unknown protein, respectively. 
The lower panel shows the western blot revealed with 2C3 as primary antibody. The material loaded 
in the lanes is identical to that in the silver nitrate stained gel except that lane 1 contains an aliquot of 
red blood cells membrane lysate.  
